Results 231 to 240 of about 57,426 (267)

Muscular dystrophy in foals*

Zentralblatt für Veterinärmedizin Reihe A, 1984
SummaryThirty‐four foals with muscular dystrophy and twelve control foals were studied. Clinical course, serum activity of aspartate aminotransferase (ASAT) and creatin kinase (CK), muscle biopsies and postmortem changes were investigated. Most cases were seen within the first three days of life. There was no sex or breed predilection.
B, Ronéus, L, Jönsson
openaire   +2 more sources

The muscular dystrophies and dystrophin

Current Opinion in Neurology, 1993
Recent progress in molecular genetics has resulted in more insight in the molecular biology of muscles and the muscular dystrophies, and has provided more reliable tools for prenatal and presymptomatic diagnosis in several disorders. The state of research is reviewed with emphasis on genetic aspects.
openaire   +2 more sources

Research in Muscular Dystrophy

Nature, 1970
Treatment of the diseases known collectively as muscular dystrophy has not proved very successful. So far, the best results have been achieved by preventive medicine, although pathological and biochemical research is beginning to yield useful information.
openaire   +2 more sources

Duchenne muscular dystrophy

Nature Reviews Disease Primers, 2021
Dongsheng Duan, Nathalie Goemans, Shin’ichi Takeda   +2 more
exaly  

Melituria in muscular dystrophy.

Rivista europea per le scienze mediche e farmacologiche = European review for medical and pharmacological sciences = Revue europeenne pour les sciences medicales et pharmacologiques, 1988
[No abstract available]
M. G. Piccardo, ANTONINI, Giovanni, MILLEFIORINI, Marcello   +2 more
openaire   +2 more sources

Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial

Nature Medicine, 2022
Kevin A Strauss, Michelle A Farrar Mbbs
exaly  

Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial

Nature Medicine, 2022
Kevin A Strauss, Michelle A Farrar Mbbs, Francesco Muntoni   +2 more
exaly  

Therapeutic approaches for Duchenne muscular dystrophy

Nature Reviews Drug Discovery, 2023
Thomas C Roberts, Kay E Davies
exaly  

Spinal muscular atrophy

Nature Reviews Disease Primers, 2022
Francesco Muntoni, Richard S Finkel
exaly  

MUSCULAR DYSTROPHIES

Continuum, 2003
openaire   +1 more source